Brentuximab vedotin
- Generic Name
- Brentuximab vedotin
- Brand Names
- Adcetris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 914088-09-8
- Unique Ingredient Identifier
- 7XL5ISS668
- Background
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug labe...
- Indication
Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin's lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or ...
- Associated Conditions
- CD30-expressing Mycosis Fungoides (MF), Classical Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma (PTCL), Primary Cutaneous Anaplastic Large Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Stage 3 Classical Hodgkin's Lymphoma
- Associated Therapies
- -
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 40
- Registration Number
- NCT01703949
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 17
- Registration Number
- NCT01700751
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 71
- Registration Number
- NCT01657331
- Locations
- 🇺🇸
Center for Lymphoid Malignancies at CUMC, New York, New York, United States
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦British Columbia Cancer Agency, Vancouver, British Columbia, Canada
Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT01620229
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease
- Conditions
- Interventions
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Brentuximab Vedotin for Steroid Refractory GvHD
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT01596218
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT01578967
- Locations
- 🇺🇸
Rex Cancer Center, Raleigh, North Carolina, United States
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
- Conditions
- Interventions
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT01578499
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 100
- Registration Number
- NCT01569204
- Locations
- 🇩🇪
1st Dept. of Medicine, Cologne University Hospital, Cologne, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.